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http://dxObjectives: This study was undertaken to identify a preferred dosing strategy for patients undergoing coronary
artery bypass grafting or valve replacement procedures with cardiopulmonary bypass.
Methods: Patients undergoing coronary artery bypass grafting, valve replacement surgery, or both were
randomly assigned to receive either standard 1-g dosing with vancomycin before and after cardiopulmonary
bypass or a single weight-based 20-mg/kg dose before surgery. The primary outcome was the percentage of
time plasma concentrations were greater than 15 mg/mL during cardiopulmonary bypass and at surgical closure.
Secondary outcomes included concentration of vancomycin in endothoracic tissue after vancomycin infusion,
average time patients had vancomycin concentrations greater than 15 mg/mL, and vancomycin plasma and tissue
pharmacokinetic parameters.
Results: Baseline characteristics were similar between the study dosing group (n¼ 10) and the standard dosing
group (n ¼ 10). From postinfusion to end of bypass, the median percentage of time vancomycin concentrations
remained greater than 15 mg/mL was 100% (interquartile range [IQR], 72.6%-100%) for weight-based dosing
versus 43.7% (IQR, 28.7%-53.4%) for standard dosing (P¼ .0005). From postinfusion to surgical closure, the
percentage of time vancomycin concentrations remained greater than 15 mg/mL was significantly higher in the
weight-based group (100% [IQR, 58.3%-100%] vs 34.6% [IQR, 25.3%-41.6%]; P ¼ .0005). Weight-based
dosing increased calculated time with vancomycin concentrations greater than 15 mg/mL and resulted in higher
endothoracic tissue vancomycin concentrations.
Conclusions: Weight-based vancomycin dosing before coronary artery bypass grafting or valve replacement
results in vancomycin concentrations greater than 15 mg/mL consistently more than does standard 1-g dosing.
(J Thorac Cardiovasc Surg 2014;147:1925-30)P
MSurgical site infections (SSIs) are estimated to add
$1.6 billion annually to health care costs and are no longer
being covered by Medicaid after coronary artery bypass
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The Journal of Thoracic and Carof methicillin-resistant Staphylococcus aureus (MRSA)
and reimbursement incentives to avoid SSIs, hospitals
commonly add vancomycin for prophylaxis in cardiac surgi-
cal procedures. One SSI study found an average per case cost
forMRSA infection of $13,901 andamortality rate of 20.7%
for MRSA infection versus 6.7% for methicillin-sensitive
S aureus.2 By adding prophylactic vancomycin and mupiro-
cin for carriers ofMRSA, one study groupwas able to reduce
wound infections after cardiac surgery by 93%.3 There is no
consensus regarding vancomycin use for prophylaxis; how-
ever, the clinical practice guidelines for antimicrobial pro-
phylaxis in surgery recommend against the routine use of
vancomycin prophylaxis in cardiac surgery unless the patient
has a b-lactam allergy or proven MRSA colonization.4 The
overall hospital-wide rate ofMRSA among S aureus isolates
at our institution is 38%, and this has been consistent for the
last 5 years. The Society of Thoracic Surgeons guidelines
state that for institutions with a high incidence of MRSA or
patients with a high risk of MRSA infection, vancomycin
would be a reasonable addition for prophylaxis during car-
diac surgical procedures (class IIB recommendation, level
of evidence C).5 The same guidelines suggest either a
weight-adjusted dose of 15 mg/kg or a fixed dose of 1 to
1.5 g within 60 minutes of surgical incision.5diovascular Surgery c Volume 147, Number 6 1925
Abbreviations and Acronyms
AUC0-end ¼ area under the concentration-time
curve from time 0 to the end of the
dosing interval
Cmax ¼ maximum drug concentration in plasma
CABG ¼ coronary artery bypass grafting
CLs ¼ systemic clearance
CPB ¼ cardiopulmonary bypass
IQR ¼ interquartile range
MIC ¼ minimum inhibitory concentration
MRSA ¼ methicillin-resistant Staphylococcus
aureus
SSI ¼ surgical site infection
Vd ¼ volume of distribution
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MPatients undergoingCABGor aortic valve replacementpro-
cedures are supported by cardiopulmonary bypass (CPB),
which leads to volume shifts. These shifts, combined with
the stress response of surgery, cause physiologic and pharma-
cokinetic alterations both during and after surgery. During
CPB, the patient experiences hemodilution, hypothermia, hy-
potension, reduction in regional bloodflow, and trauma,which
causes an acute increase in the volume of drug distribution,
reduction in drug clearance, and alteration of protein
binding.6,7 These changes lead to alterations in vancomycin
plasma and tissue concentrations with resultant variations in
pharmacodynamic target attainment during cardiac surgery.
Our study aimed to compare a weight-based dosing strat-
egy with the standard dosing strategy and to gain further un-
derstanding of the pharmacokinetics of vancomycin during
CPB, as well as to evaluate endothoracic tissue concentra-
tions 30 minutes after the end of vancomycin infusion.
MATERIALS AND METHODS
This study was conducted between January 2011 and June 2011 at the
University of Colorado Hospital and was approved by the Colorado Multi-
ple Institutional Review Board. Written, informed consent was obtained
from all patients. The datawere collected and analyzed by the investigators.
Study Patients
Patients between the ages of 18 and 89 years who were scheduled to un-
dergo CABG, valve replacement surgery, or both and who did not meet any
of the exclusion criteria were eligible for this study. Exclusion criteria
included patient allergy or hypersensitivity to vancomycin, impaired renal
function (creatinine clearance less than 40 mL/min according to the
Cockcroft-Gault equation), and inability to provide consent. Perioperative
infusion-related adverse effects of vancomycin were monitored until the
morning after surgery.
Treatment Assignments
Patientswere randomly assigned after consent to receive either a standard
1-g dose of vancomycin with a second 1-g dose to be given after CPB, or a
20-mg/kg initial dose of vancomycin determined by actual bodyweight with
a maximum dose of 2 g. Body weights and laboratory values were obtained
the morning of surgery. The vancomycin dose was prepared by the study1926 The Journal of Thoracic and Cardiovascular Surinvestigators and given to a nurse for administration. The dosing was not
blinded and was known by everyone involved in the surgery. The initial van-
comycin dose was infused during the course of 90 minutes and was
completed shortly before incision. In addition, patients from both arms
were administered cefazolin for prophylaxis according to hospital protocol.
Blood and Tissue Collection
As many as 5 blood samples (5 mL) were drawn throughout the surgery
for determination of vancomycin concentrations. The first blood sample
was collected after the infusion of the first dose of vancomycin. A second
sample was collected 15 minutes after the start of CPB, with a third sample
collected 45 minutes after the start of CPB. A fourth blood sample was
drawn after the end of CPB. This blood sample was immediately sent to
the hospital clinical laboratory for analysis. Patients in the weight-based
group who had a vancomycin concentration less than 15 mg/mL were given
an additional 1-g dose of vancomycin immediately. The patients in the
weight-based group with a plasma vancomycin concentration greater
than 15 mg/mL were not given a second dose until 12 hours after the initial
dose, as part of the 3 postoperative vancomycin doses per hospital protocol.
All patients in the standard dosing group received a second 1-gram vanco-
mycin dose after the end of CPB during surgical closure. For patients
assigned to the weight-based group who did not require an immediate sec-
ond vancomycin dose, a fifth sample was obtained approximately 2 hours
after the fourth sample to assist with the pharmacokinetic analysis. In addi-
tion to the blood sampling, a single sample of endothoracic fascia was
collected at the surgeon’s discretion, with a target of 30 minutes after the
conclusion of the first vancomycin infusion.
After the pharmacokinetic analysis, patients of both arms of the study
were then placed on a regimen of vancomycin 1 g every 12 hours for a total
of 3 postoperative doses of vancomycin according to hospital protocol. For
patients in the 20-mg/kg dose arm who did not require a second dose, 1 g of
vancomycin was administered 12 hours after the first dose.
Sample Storage and Analysis
Plasma was obtained from whole blood samples not immediately
analyzed by the hospital laboratory. Plasma and endothoracic tissue sam-
ples were stored at 80C until analysis. Vancomycin concentrations
were determined in the plasma and homogenate by means of liquid chro-
matography–mass spectrometry. The method used an Applied Biosystems
Sciex 4000 (Applied Biosystems, Foster City, Calif) equipped with a Shi-
madzu HPLC (Shimadzu Scientific Instruments, Inc, Columbia, Md) and
Leap auto-sampler (LEAP Technologies, Carrboro, NC). Liquid chroma-
tography used a Zorbax extended-C8 503 4.6-mm column, 5-mm particle
size (Agilent Technologies, Inc, Santa Clara, Calif), equipped with a C8
column guard and operated at 40C with a flow rate of 0.4 mL/min. The
mobile phase consisted of solvent A, 10-mmol/L ammonium acetate and
0.1% formic acid in water, and solvent B, 50:50 acetonitrile and methanol.
Between samples, the auto sampler was washed with a 1:1:1:1 mixture of
acetonitrile, methanol, isopropyl alcohol, and water containing 0.1%
formic acid. The chromatographic method used was 95% solvent A for
0.50 minutes, brought to 40% solvent B at 5.00 minutes and held for
1.00 minutes, ramped to 95% solvent B at 7.00 minutes and held for
1.00 minutes, then brought back to 95% solvent A at 8.50 minutes and
held for 1.00 minutes (9.50 minutes total run time).
Human serum (control) was used to prepare standard curves and quality
control samples. These samples were extracted and processed in an analo-
gous fashion as the in vivo samples. An extraction solution containing in-
ternal standard (ceftazidime) was freshly prepared in a 100-mL volumetric
flask containing a 2:1 (vol/vol) mixture of 1:1 acetonitrile and methanol
and water. In individual sets, the samples were removed from the freezer
where they had been stored at 80C  10C and allowed to thaw on
ice for 40 to 45 minutes. The tubes were vortex mixed for 5 seconds, and
a sample (250 mL) was transferred to an Eppendorf tube (1.5 mL) and
mixed with extraction solution (500 mL), vortex mixed for 5 seconds, setgery c June 2014
TABLE 1. Patient baseline characteristics
Weight based
(n ¼ 10)
Standard
(n ¼ 10) P value
Age (y) 62 (56-73) 62 (56-71) .83
Male 7 (70%) 6 (60%) .95
Weight (kg) 88 (81-106) 82 (75-88) .5
Serum creatinine (mg/dL) 0.92 (0.81-1.14) 0.85 (0.78-0.91) .5
Creatinine clearance per
Cockcroft-Gault
(mL/min)
98 (91-109) 99 (86-106) .98
Vancomycin dose
Total (mg) 1750 (1625-2000) 1000 (1000-1000) <.0001
By weight (mg/kg) 20.0 (18.9-20.0) 12.1 (11.4-13.3) <.0001
Cardiopulmonary
bypass time (h)
3.1 (2.6-4.6) 2.9 (2.7-3.9) .96
Values are presented as number and percentage of patients or median and interquartile
range.
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Mat room temperature for 5 minutes, vortex mixed a second time for 5 sec-
onds, and then centrifuged at 13,000 rpm for 10 minutes with an Eppendorf
minispin centrifuge (Eppendorf AG, Hamburg, Germany). The superna-
tants were transferred into individual wells of a 96-well plate. The 96-
well plate was placed into the LEAP auto-sampler coo stack (6.0C 
0.1C), and samples (10 mL) were analyzed with liquid chromatography–
mass spectrometry.
Plasma concentration-time data for vancomycin were analyzed by stan-
dard noncompartmental pharmacokinetic methods, with elimination of
vancomycin assumed to be first order. Maximum drug concentration in
plasma (Cmax) and the time at which Cmax was achieved were estimated
by visual inspection of the plasma concentration-time data. The apparent
terminal elimination rate constant (kel) was determined by least-squares
regression analysis of the terminal portion of the natural log
concentration-time curve. Elimination half-life (T1/2) was calculated as
0.693/kel. The area under the concentration-time curve from time 0 to
the end of the dosing interval (AUC0-end) was calculated by the linear trap-
ezoidal summation method. Total systemic clearance (CLs) was calculated
as dose/AUC0-end. Because the vancomycin concentrations were not at
steady state, the volume of distribution (Vd) was calculated by non–steady
state methods.
Vancomycin tissue penetration calculations were made by dividing the
direct measured tissue concentration by the extrapolated calculated vanco-
mycin plasma concentration at the time of tissue collection. Results were
reported as a ratio in the form of a percentage to demonstrate the degree
of tissue penetration to endothoracic tissue.
End Points
The primary study outcome was the percentage of time vancomycin
plasma concentrations resulting from each of the dosing strategies re-
mained greater than 15 mg/mL. This percentage was assessed relative to
2 distinct time frames: the time from the end of the vancomycin infusion
until the end of CPB and the time from the end of the vancomycin infusion
until the time of the closure of surgical incision. Secondary outcomes
included the average amount of time that vancomycin concentrations re-
mained greater than 15 mg/mL in each dosing group, the number of patients
in each group who still had a concentration greater than 15 mg/mL at the
end of CPB, vancomycin concentrations in the endothoracic tissue, vanco-
mycin penetration into endothoracic tissue, and pharmacokinetic values of
vancomycin during surgery.
Statistical Analysis
Datawere analyzed with Fisher exact test andMann-WhitneyU tests for
categorical and continuous data as appropriate. Kaplan-Meier analysis with
log-rank test was used to analyze the percentage of patients maintaining
vancomycin concentrations greater than 15 mg/mL with time. With an ex-
pected SD of 25, 10 patients in each group were required to obtain 80%
power to demonstrate an absolute improvement of 25% in the percentage
of time plasma concentrations remained greater than 15 mg/mL. Data were
reported as median with interquartile range (IQR) for data not normally
distributed. Statistical analysis was conducted with SAS (version 9.3;
SAS Institute, Inc, Cary, NC) and GraphPad Prism (version 5.01; GraphPad
Software, Inc, San Diego, Calif) software packages. All tests were 2-sided.
RESULTS
Of the 25 screened patients, 20 underwent random
assignment after providing informed consent. The weight-
based group consisted of 5 patients who underwent
CABG, 4 who underwent aortic valve replacement, and 1
who underwent both procedures. The standard group had
6 patients who underwent CABG procedures and 4 patients
who underwent aortic valve replacement. Of the 5 patientsThe Journal of Thoracic and Carscreened who were not included in the study, 3 had renal
function lower than 40 mL/min and 2 refused consent. No
patients were receiving vancomycin before the day of sur-
gery. Overall, 10 patients received the standard dosing
scheme of 1 g vancomycin before surgery and 1 g after
the end of CPB and 10 patients received a weight-based
vancomycin dose of 20 mg/kg.
Patient baseline characteristics are summarized inTable 1.
Overall, the study contained 65% men, and patients in the
weight-based group received almost 8 mg/kg more vanco-
mycin than did those in the standard dosing group. In the
weight-based group, 6 patients received a 20-mg/kg dose
that ranged from 1300 to 1800 mg; the other 4 received the
maximum dose of 2 g, which translated to an actual
weight-based dose of 17.5 to 19.2 mg/kg. The median time
from the end of the first vancomycin infusion until the end
of CPB was similar between groups: 3.1 hours (IQR, 2.6-
4.6 hours) in the weight-based group versus 2.9 hours
(IQR, 2.7-3.9 hours) in the standard group (P ¼ .96). There
were no statistical differences in renal function, serum creat-
inine, or weight between the groups.
Primary and secondary study outcomes are summarized
in Table 2. The percentage of time with vancomycin con-
centrations greater than 15 mg/mL was increased in the
weight-based group relative to the standard dose group.
From postinfusion to the end of CPB, the median percent-
age of time with a vancomycin concentration greater than
15 mg/mL for weight-based dosing versus standard dosing
was 100% (IQR, 72.6%-100%) versus 43.7% (IQR,
28.7%-53.4%; P ¼ .0005). From postinfusion to surgical
closure, the percentage of time vancomycin concentrations
remained greater than 15 mg/mL was significantly higher in
the weight-based dosing group (100% [IQR 58.3%-100%]
vs 34.6% [IQR, 25.3%-41.6%]; P¼ .0005). Weight-based
dosing increased the number of patients with vancomycin
concentrations greater than 15 mg/mL after the end ofdiovascular Surgery c Volume 147, Number 6 1927
TABLE 2. Study outcomes
Weight based Standard P value
Time of>15 mg/mL from infusion end to bypass end (%) 100 (72.6-100) 43.7 (28.7-53.4) .0005
Vancomycin plasma concentration at end of bypass (mg/mL) 21.3 (19.3-27.1) 12.5 (8.7-13.9) .0005
Time of>15 mg/mL from infusion end to surgical closure (%) 100 (58.3-100) 34.6 (25.3-41.6) .0005
Vancomycin plasma concentration at surgical closure (mg/mL) 18.8 (15.8-24.8) 10.5 (7.5-12.7) .0006
Average duration of>15 mg/mL concentration (h) 4.0 (2.7-5.5) 1.4 (1.2-1.6) .0003
Patients with>15 mg/mL after bypass (%) 6 (60%) 0 (0%) <.0001
Endothoracic fascia vancomycin concentration (mg/g tissue) 24.5 (10.8-31.4) 9.1 (7.2-11.6) .01
Vancomycin endothoracic fascia penetration (%) 73 (34-87) 54 (47-85) .25
Values are reported as number and percentage of patients or median and interquartile range. All endothoracic tissue data were derived from single collection 30 minutes after
initial vancomycin infusion. Collection times of endothoracic fascia samples were not significantly different between groups.
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MCPB (60% in the weight-based group vs 0% in the standard
group; P<.0001) and also the median calculated time that
patients had vancomycin concentrations greater than 15 mg/
mL (4.0 hours in the weight-based group [IQR, 2.7-5.5
hours] vs 1.4 hours in the standard group [IQR, 1.2-1.6
hours]; P ¼ .0003). No patients in the fixed-dose group
maintained vancomycin concentrations greater than 15
mg/mL for longer than 2.2 hours (Figure 1). Figure 2 shows
the average vancomycin concentrations throughout surgery
in both groups, with the weight-based group averaging
higher plasma concentrations throughout the surgery.
The median endothoracic tissue vancomycin concentra-
tion after weight-based dosing versus standard dosing was
24.5 mg/g tissue (IQR, 10.8-31.4 mg/g tissue) versus 9.1
mg/g tissue (IQR, 7.2-11.6 mg/g tissue; P ¼ .01). Tissue
collection times were similar between the weight-based
and standard groups (0.33 hours after vancomycin infusion
[IQR 0.22-1.03 hours] vs 0.16 hours [IQR, 0.02-0.75
hours]; P ¼ .21), allowing comparative analysis of the
dosing groups. Calculated plasma concentrations at the
time of tissue collection in the weight-based group versusFIGURE 1. Patients with a plasma vancomycin concentration remaining
greater than 15 mg/mL over time for each dosing regimen. Vanc, Vancomy-
cin; HR, hazard ratio; CI, confidence interval.
1928 The Journal of Thoracic and Cardiovascular Surthe standard group were 47.5 mg/mL (IQR, 35.2-52.5
mg/mL) versus 33.4 mg/mL (IQR, 27.4-37.8 mg/mL;
P ¼ .06). Vancomycin penetration to tissues, shown in
Figure 3, was similar between the groups: 73% of simulta-
neous plasma concentrations in the weight-based group
(IQR, 34%-87%) versus 54% in the standard group
(IQR, 47%-85%; P ¼ .25). Assuming consistent penetra-
tion of vancomycin into endothoracic tissue, tissue concen-
trations at surgical closure were 16.8 mg/g tissue (IQR,
6.1-19.4 mg/g tissue) versus 5.6 mg/g tissue (IQR, 4.5-7.1
mg/g tissue) in the weight-based dosing and standard dosing
groups, respectively (P ¼ .01).
The calculated pharmacokinetic parameters for each
group are shown in Table 3. A highermedian calculated van-
comycin AUC0-end was calculated for the weight-based
group (228.3 mg ∙ h/L [IQR 202.0-291.5 mg ∙ h/L] than
for the standard group 142.9 mg ∙ h/L [IQR 103.1-211.8
mg ∙ h/L]; P ¼ .02). There were no significant differences
between the subject groups in vancomycin t1/2 (3.2 hours
for weight-based group [IQR 2.4-5.6 hours] vs 4.1 hoursFIGURE 2. Mean serum vancomycin concentration over time for each
dosing regimen. SD, Standard deviation.
gery c June 2014
FIGURE 3. Tissue penetration values for each patient in weight-based
(diamonds) and standard (squares) dosing groups. Median tissue penetra-
tion values for weight-based (dashed line) and standard (solid line) dosing
groups are also shown.
Hafermann et al Perioperative Managementfor standard group [IQR, 2.8-5.8 hours]; P ¼ .32), Vd (0.41
L/kg for weight-based group [IQR, 0.36-0.59 L/kg] vs 0.54
L/kg for standard group [IQR, 0.48-0.64 L/kg]; P ¼ .052),
CLs (1.43 mL/min/kg for weight-based group [IQR, 1.10-
1.79 mL/min/kg] vs 1.51 mL/min/kg for standard group
[IQR, 1.13-1.91 mL/min/kg]; P ¼ .74), or Cmax (47.4 mg/
mL for weight-based group [IQR, 35.2-25.6 mg/mL] vs
33.4 mg/mL for standard group [IQR, 27.4-37.8 mg/mL];
P ¼ .13). There were no adverse perioperative infusion-
related effects, including redman syndrome, in either group.P
MDISCUSSION
Although previous studies have evaluated plasma vanco-
mycin concentrations in cardiac surgery after standard8,9
and weight-based doses,10,11 the dosing methods have not
previously been directly compared in a single study. This
study evaluated a larger initial weight-based dose of vanco-
mycin (20 mg/kg) than the recommended Society of
Thoracic Surgeons guideline dose of 15 mg/kg.5 The study
dose was derived from the 2011 MRSA treatment guide-
lines from the Infectious Diseases Society of America and
American Society of Health System Pharmacists, which
recommend vancomycin doses of 15 to 20 mg/kg every 8
to 12 hours to achieve an AUC0-24 to minimum inhibitory
concentration (MIC) ratio greater than 400 for organismsTABLE 3. Vancomycin pharmacokinetic values
T1/2 (h) Vd (L/kg) CLs
Weight based 3.2 (2.4-5.7) 0.41 (0.36-0.59) 1.4
Standard 4.1 (2.8-5.8) 0.54 (0.48-0.64) 1.5
P value .32 .052
Values are reported as median and interquartile range. Values were calculated by standard n
to be first order. T1/2, Half-life; Vd, volume of distribution; CLs, systemic clearance; AUC0-en
end of dosing interval; Cmax, peak vancomycin concentration.
The Journal of Thoracic and Carwith an MIC of 1 or less.12 Our findings indicate that
weight-based vancomycin dosing improves the amount of
time vancomycin concentrations remain therapeutic during
cardiac surgery and provides higher endothoracic tissue
vancomycin concentrations relative to a standard 1-g
dose. This was an expected finding because of the larger
median vancomycin dose in the weight-based group (20
mg/kg) than in the standard dosing group (12.1 mg/kg).
Current fixed-dose vancomycin prophylaxis has not adapted
to increasing average patient weights, often resulting in sub-
therapeutic vancomycin concentrations intraoperatively
when a standard 1-g dose is used.
The target vancomycin concentration was extrapolated
from the Infectious Diseases Society of America and
American Society of Health System Pharmacists MRSA
treatment guidelines, which recommend trough vancomycin
concentrations of 15 to 20 mg/mL for serious infections
including bacteremia, infective endocarditis, osteomyelitis,
meningitis, pneumonia, and severe skin and soft-tissue infec-
tions.12 We considered that the time frames measured, from
the end of vancomycin infusion to the end of CPB and from
the end of vancomycin infusion to the time of surgical
closure, were both significant measurements for surgical
prophylaxis. Previous studies have focused on maintaining
vancomycin concentrations greater than the MICs of
common gram-positive pathogens found in SSIs.8,13,14
There have been several different weight-based preopera-
tive vancomycin dosing strategies used in cardiac surgery
with CPB. In 1983 Farber and colleagues10 evaluated vanco-
mycin dosing regimens of 7 mg/kg versus 15 mg/kg and
determined that the higher dose should be used to achieve
appropriate plasma concentrations. Higher dosing strategies
also stem from studies showing that vancomycin concentra-
tions may decrease from 11% to 41% after the start of
CPB because of hemodilution and sequestration of vancomy-
cin by the bypass circuit.11,13,15 In our study, we used a larger
preoperative weight-based dose of 20 mg/kg to target higher
plasma concentrations, and a maximum dose of 2 g was im-
plemented to avoid the potential for increased side effects.
This resulted in substantially higher vancomycin concentra-
tions at the beginning of CPB, at the end of CPB, and at the
time of surgical closure compared to patients receiving a stan-
dard 1-g dose. These findings appear to be consistent when
one compares the results of our weight-based dosing group
with previous studies that evaluated a fixed 1-g vancomycin(mL/min/kg) AUC0-end (mg ∙ h/L) Cmax (mg/mL)
3 (1.10-1.79) 228.3 (202.0-291.5) 47.4 (35.2-52.6)
1 (1.13-1.91) 142.9 (103.1-211.8) 33.4 (27.4-37.8)
.74 .02 .13
oncompartmental pharmacokinetic methods with elimination of vancomycin assumed
d, area under the concentration-time curve from start of vancomycin infusion until the
diovascular Surgery c Volume 147, Number 6 1929
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Mdose.With a 1-g vancomycin dose before cardiac surgery,Or-
tega and coworkers8 found an average vancomycin concen-
tration of 11.07  5.88 mg/mL at the beginning of CPB and
7.13  2.10 mg/mL 12 hours after vancomycin infusion. A
recent study found an average plasmavancomycin concentra-
tion of 10.1 mg/mL at the time of wound closure in 215 pa-
tients undergoing on-pump cardiac surgery who received a
1-g prophylactic dose of vancomycin.9
Our study evaluated vancomycin penetration into endo-
thoracic tissue and found median penetrations of 73%
and 54% in the weight-based and standard groups, respec-
tively. This finding was comparable to a previous study,
which found 30% to 60% vancomycin penetration into
sternal bone and similar penetrations into thoracic wall
fat.15 Endothoracic tissue penetration was as low as 28%
in our study, which resulted in inadequate vancomycin tis-
sue concentrations in the standard 1-g dosing group at the
time of surgical closure.
There were no adverse events in either group that could
be attributed to vancomycin; however, this was not the pri-
mary intent of our study and therefore it was not powered
for detection of safety outcomes. Pharmacokinetic proper-
ties were analyzed for all patients involved in the study.
As seen in Table 3, the t1/2, Vd, CLs, and Cmax were similar
between groups. The AUC0-end was higher in the study dose
group, which may have been due to the higher vancomycin
doses. Overall, the pharmacokinetic values are comparable
to those in previous studies evaluating vancomycin during
cardiac surgery.8,14
Therewere several limitations identified during the study.
This study was not blinded and evaluated only 20 patients
undergoing CABG, aortic valve replacement, or both.
Because of the nature of the procedures, the durations of sur-
gery and CPB varied among patients, as did study patients’
weights, which ranged from 55 to 123 kg. The patients had
varying renal function, which was further complicated by
the fact that study patients averaged older than 60 years in
both groups. Although several measures were taken to
obtain uniform blood draw times, there was still variability
in times as a result of complications during surgery.
Although recent guidelines for antimicrobial prophy-
laxis in surgery have discouraged the routine use of vanco-
mycin for prophylaxis, vancomycin is still recommended
for patients with known colonization of MRSA and as
an alternative to cefazolin for patients with a documented
b-lactam allergy.4 Our study showed that standard dosing
of vancomycin during CPB-assisted cardiac surgical pro-
cedures results in inconsistent and potentially subthera-
peutic levels of vancomycin during surgery. A larger
weight-based dosing schema (20 mg/kg) was used than
that in previous studies; this resulted in higher levels
throughout surgery without any observed adverse effects.
Our findings suggest that the standard 1-gram dosing of1930 The Journal of Thoracic and Cardiovascular Survancomycin may be insufficient for prophylaxis in cardiac
surgery and may lead to increased infections. This study
also showed a correlation in endothoracic tissue concen-
trations and plasma concentrations, with higher tissue con-
centrations observed in the weight-based dosing group.
Although no consensus exists regarding the use of vanco-
mycin for patients undergoing CPB surgery, our study sug-
gests that patients receiving a weight-based dosing
regimen are more likely to maintain favorable plasma
and tissue concentrations and that this therefore may be
a preferred dosing method when vancomycin is to be
used. This finding suggests that the current Society of
Thoracic Surgeons guidelines may need to revise their rec-
ommendations to endorse a weight-based vancomycin
dosing strategy in preference to fixed dosing; however,
larger studies are needed to validate the clinical impact
of this strategy on the incidence of surgery-related infec-
tions and determine potential safety differences.References
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